Sector News

ThromboGenics Appoints Emmanuele Attout as Independent Non-Executive Director

January 23, 2015
Life sciences
(GLOBE NEWSWIRE) – ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces that its Board of Directors has nominated Emmanuèle Attout to be its new Independent non-executive director.  Mrs. Attout will join the Audit Committee of the Company.   
 
Mrs. Attout has been an audit partner at PricewaterhouseCoopers since 1994. She has been in charge of audits of a range of clients including banks, insurance companies, investment funds and assets managers.  She has in recent years been in charge of the audits of listed pharmaceuticals companies and life sciences business out of which she brings substantial relevant experience to the Board and to the Audit Committee.  
 
Dr Staf Van Reet, Chairman of ThromboGenics’ Board of Directors, said: “We are delighted to welcome Emmanuèle to the ThromboGenics’ board as a non-executive director. Her broad business and financial experience, will be extremely valuable to our Board and Audit Committee as we work to execute the standalone strategy we announced in mid-2014.”
   
Commenting on her appointment, Mrs. Attout said: “I am very pleased to be joining the ThromboGenics Board. I have been impressed by the clear strategy that the Company has outlined to build a profitable business focused on providing innovative medicines for the treatment of a number of important vitreo-retinal diseases and I am looking forward to contributing to its successful execution.”
 
Source: ThromboGenics

comments closed

Related News

October 23, 2021

Novo Nordisk teams with CVS Health on obesity support program ahead of Wegovy DTC launch

Life sciences

As Novo Nordisk gears up to disrupt the obesity market with its newly approved weight-loss drug Wegovy, it is teaming with retail pharmacy giant CVS Health on a new education and nutrition coaching program for people taking anti-obesity meds.

October 23, 2021

GSK-backed Atreca inks license with Gates Medical Research Institute for malaria monoclonal antibody

Life sciences

The terms of the deal were undisclosed, but Atreca received $6 million from the Gates Foundation in 2012 to discover potential treatments for malaria, tuberculosis and HIV. The foundation has also given grant money to other biopharmas exploring malaria treatments, including Exscientia, which secured $4.2 million last year for such work.

October 23, 2021

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

At the start of the last decade, the IPO markets weren’t receptive to biotech companies. But by 2013, public investment was pouring into the industry, drawn by scientific advances and boosted by the newfound interest of a broader range of investors. Ever since, biotechs and their backers have ridden a multi-year boom. Keep track of them as they happen with this database.

Send this to a friend